hero image

CORRECTING and REPLACING Biogen to Present at Bank of America Merrill Lynch Global Healthcare Conference London

September 10, 2015 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--First paragraph, second sentence of release should read: The webcast will be live on Friday, September 18, 2015 at 10:40 a.m. BST (5:40 a.m. ET.)

The corrected release reads:

BIOGEN TO PRESENT AT BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE LONDON

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at Bank of America Merrill Lynch Global Healthcare Conference London. The webcast will be live on Friday, September 18, 2015 at 10:40 a.m. BST (5:40 a.m. ET.) To access the live webcast, please visit Biogen’s Investors section at www.biogen.com. An archived version of the webcast will be available for 14 days following the presentation.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.

 

Contact:

Biogen
Karen Jewell, 781-464-2442
Investor Relations

thumb
April 25, 2024
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human

thumb
April 24, 2024
Biogen Reports First Quarter 2024 Results